Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

NCT05515315 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Immunotherapy Esophagus Cancer

Interventions

DRUG: Tislelizumab
DRUG: Albumin paclitaxel
DRUG: Nedaplatin
RADIATION: radiotherapy

Sponsor

Fuzhou General Hospital